Supplementary Figure 2 from Combination Immunotherapy after ASCT for Multiple Myeloma Using MAGE-A3/Poly-ICLC Immunizations Followed by Adoptive Transfer of Vaccine-Primed and Costimulated Autologous T CellsAaron P. Rapoport, Carl H. June, Nicole A. Aqui et al.|Unknown|2023Cited by 0
Supplementary Figure Legends from Combination Immunotherapy after ASCT for Multiple Myeloma Using MAGE-A3/Poly-ICLC Immunizations Followed by Adoptive Transfer of Vaccine-Primed and Costimulated Autologous T CellsAaron P. Rapoport, Carl H. June, Nicole A. Aqui et al.|Unknown|2023Cited by 0
Supplementary Table 1 from Combination Immunotherapy after ASCT for Multiple Myeloma Using MAGE-A3/Poly-ICLC Immunizations Followed by Adoptive Transfer of Vaccine-Primed and Costimulated Autologous T CellsAaron P. Rapoport, Carl H. June, Nicole A. Aqui et al.|Unknown|2023Cited by 0
Supplementary Figure 3 from Combination Immunotherapy after ASCT for Multiple Myeloma Using MAGE-A3/Poly-ICLC Immunizations Followed by Adoptive Transfer of Vaccine-Primed and Costimulated Autologous T CellsAaron P. Rapoport, Carl H. June, Nicole A. Aqui et al.|Unknown|2023Cited by 0
Supplementary Figure 1 from Combination Immunotherapy after ASCT for Multiple Myeloma Using MAGE-A3/Poly-ICLC Immunizations Followed by Adoptive Transfer of Vaccine-Primed and Costimulated Autologous T CellsAaron P. Rapoport, Carl H. June, Nicole A. Aqui et al.|Unknown|2023Cited by 0